Zhitong Finance App News, Lizhu Pharmaceutical (01513) issued an announcement. Recently, the company's holding subsidiary, Zhuhai Lizhudan Antibiotic Technology Co., Ltd. (Lizumab), received the “Drug Registration Certificate” (certificate number: 2026S03179) approved and issued by the State Drug Administration. Leconchitazumab injection (subcutaneous injection) was jointly developed by Lizhumab and Beijing Xinkanghe Biomedical Technology Co., Ltd., as a recombinant anti-human IL-17A/F humanized monoclonal antibody injection. It is the first IL-17A/F dual-target innovative biologic preparation independently developed by China. It can act by simultaneously blocking the inflammatory factors of IL-17A and IL-17F. The indications for this registration application are: suitable for adult patients with moderate to severe plaque psoriasis receiving systematic treatment or phototherapy.

This product has completed a phase III clinical trial for moderate to severe plaque psoriasis. The study used scuchiumab as a positive control. The data showed that this product was superior to the control group in terms of efficacy rate, skin clearance rate, and long-term efficacy, and the safety was comparable to that of the control group. This product does not require an initial intensive induction period, and the frequency of administration is reduced compared to the control group, which can improve the patient's user experience and improve compliance.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.